A. Fromont

发表

Geographic variations of multiple sclerosis in France.

S. Vukusic, C. Confavreux, C. Bonithon-Kopp, 2010, Brain : a journal of neurology.

Epidemiology of multiple sclerosis.

E. Leray, G. Edan, A. Fromont, 2016, Revue neurologique.

[Focal subarachnoid hemorrhage and cerebral amyloid angiopathy: a non-fortuitous association].

M. Giroud, F. Ricolfi, A. Fromont, 2010, Revue neurologique.

Artificial intelligence to predict clinical disability in patients with multiple sclerosis using FLAIR MRI.

O. Commowick, C. Barillot, A. Tucholka, 2020, Diagnostic and interventional imaging.

Mitochondrial dysfunctions in 7-ketocholesterol-treated 158N oligodendrocytes without or with α-tocopherol: Impacts on the cellular profil of tricarboxylic cycle-associated organic acids, long chain saturated and unsaturated fatty acids, oxysterols, cholesterol and cholesterol precursors

A. Vejux, G. Lizard, A. Fromont, 2017, The Journal of Steroid Biochemistry and Molecular Biology.

[Contribution of the Dijon Stroke Registry after 20 years of data collection].

Y. Béjot, M. Giroud, O. Rouaud, 2008, Revue neurologique.

Attenuation of 7-ketocholesterol-induced overproduction of reactive oxygen species, apoptosis, and autophagy by dimethyl fumarate on 158N murine oligodendrocytes

A. Vejux, G. Lizard, P. Andreoletti, 2017, The Journal of Steroid Biochemistry and Molecular Biology.

Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing BRAFV600E -Mutated Erdheim–Chester Disease: A Case Report

A. Idbaih, B. Bonnotte, A. Fromont, 2022, Frontiers in Immunology.

[Pregnancy and multiple sclerosis].

A. Fromont, T. Moreau, S. Brunot, 2010, Presse medicale.

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

S. Vukusic, B. Brochet, D. Brassat, 2014, JAMA neurology.

A prospective observational post‐marketing study of natalizumab‐treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort

P. Vermersch, M. Clanet, B. Brochet, 2014, European journal of neurology.

National estimate of multiple sclerosis incidence in France (2001–2007)

I. Fournel, A. Weill, C. Binquet, 2012, Multiple sclerosis.

Trends in the Incidence of Transient Ischemic Attacks, Premorbid Risk Factors and the Use of Preventive Treatments in the Population of Dijon, France from 1985 to 2004

Y. Béjot, M. Giroud, O. Rouaud, 2006, Cerebrovascular Diseases.

[Cost of multiple sclerosis in France].

A. Weill, C. Binquet, A. Fromont, 2014, Revue neurologique.

[Long-lasting and isolated Uhthoff's phenomenon after effort preceding multiple sclerosis].

C. Confavreux, A. Fromont, T. Moreau, 2010, Revue neurologique.

Cancer and multiple sclerosis in the era of disease-modifying treatments

P. Vermersch, L. Rumbach, D. Brassat, 2011, Journal of Neurology.

Disability progression in multiple sclerosis patients using early first‐line treatments

E. Leray, S. Vukusic, E. Thouvenot, 2022, European journal of neurology.

Comorbidities at multiple sclerosis diagnosis

A. Weill, C. Binquet, A. Fromont, 2013, Journal of Neurology.

Multiple Sclerosis

A. Fromont, T. Moreau, 2016, Methods in Molecular Biology.

High efficiency and clinical relevance of exome sequencing in the daily practice of neurogenetics

Y. Béjot, M. Giroud, L. Faivre, 2021, Journal of the Neurological Sciences.

What has changed for stroke at the beginning of the 21st century

Y. Béjot, M. Giroud, O. Rouaud, 2009 .

Epidemiology of stroke in Europe: Geographic and environmental differences

Olivier Rouaud, Y. Béjot, M. Giroud, 2007, Journal of Neurological Sciences.

Inflammatory demyelinating events following treatment with anti-tumor necrosis factor.

A. Fromont, T. Moreau, J. de Seze, 2009, Cytokine.

Delay from treatment start to full effect of immunotherapies for multiple sclerosis.

L. Kappos, P. Vermersch, E. Leray, 2020, Brain : a journal of neurology.

Natalizumab-PML survivors with subsequent MS treatment

C. Louapre, D. Brassat, B. Stankoff, 2017, Neurology: Neuroimmunology & Neuroinflammation.

Clinical Parameters to Predict Response to Interferon in Relapsing Multiple Sclerosis

G. Le Teuff, C. Quantin, C. Binquet, 2008, Neuroepidemiology.

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy

P. Vermersch, S. Vukusic, B. Brochet, 2016, Neurology.

[A neurological deficit multifocal pseudo infectious revealing a disseminated acute encephalomyelitis].

M. Giroud, B. Bonnotte, A. Fromont, 2008, Presse medicale.

[Subjective quality of life profile in patients with multiple sclerosis].

K. Chahraoui, A. Fromont, T. Moreau, 2010, Revue neurologique (Paris).

Anti-Argonaute antibodies as a potential biomarker in NMOSD

A. Fromont, R. Marignier, N. Derache, 2023, Journal of Neurology, Neurosurgery, and Psychiatry.